The former name is technically overbought but offers reasons to expect it to grow, while the latter should benefit from the Covid-19 vaccines.
CMPS may be a company representing the true cannabis 2.0. The irony in that is it isn't a cannabis company but rather a play on psilocybin.
Let's review the charts and indicators.
The shares have been digesting and consolidating the gains achieved in early November.
Our latest analysis and trading strategy for the cloud healthcare software provider.
Here are five picks in a sector whose private- and public-sector support is sure to continue as Asia ages.
The charts are generally bullish and HCA could head up towards $200, but there are some caveats.
The shares have doubled from their March nadir.
My preference here is to target an option that will work more like a stock replacement approach.
A look at the fast-growing field of telehealth, both for people and, as a less-well known market, for pets.